Previous 10 | Next 10 |
Thinly traded micro cap Axovant Gene Therapies (NASDAQ: AXGT ) is up 17% premarket on light volume in reaction to results from one child with GM1 gangliosidosis who received gene therapy candidate AXO-AAV-GM1. More news on: Axovant Gene Therapies Ltd., Healthcare stocks news,...
NEW YORK and BASEL, Switzerland, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single patient with GM1 gangliosidosis was administered investigational AXO-AAV-GM1 gene therapy. ...
Gene therapy is a biological product that mediates its effect by transcription and/or translation of transferred genetic material by integrating into the host genome. It is administered as nucleic acids, viruses, or genetically engineered microorganisms. In gene therapy, a normal gene is inserte...
NEW YORK and BASEL, Switzerland, Dec. 03, 2019 (GLOBE NEWSWIRE) -- New loan amendment reduces loan obligation by 50% without penalty, eliminates minimum cash covenant, and extends interest-only period for 9 months Debt service burden reduced by approximately $2.0 million per month dur...
The FDA has granted orphan drug designation to Axovant Gene Therapies' (NASDAQ: AXGT ) AXO-AAV-GM1, for the treatment of GM1 gangliosidosis. More news on: Axovant Gene Therapies Ltd., Healthcare stocks news, Read more ...
NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company&...
Continuing with the series of articles on gene therapy, this article will discuss the various delivery methods for gene therapies with a focus on viral vectors. What is transgene? A transgene is a new therapeutic DNA segment that is to be inserted into the host cell. In addition to the g...
Axovant Gene Therapies (NASDAQ: AXGT ): Q3 GAAP EPS of -$0.61 beats by $0.43 . Cash and cash equivalents of $60.3M Press Release More news on: Axovant Gene Therapies Ltd., Earnings news and commentary, ,
First evidence of clinical stabilization in two children with Tay-Sachs disease that received AXO-AAV-GM2 presented at ESGCT in October 2019 Continued enrollment of patients in AXO-AAV-GM1 registrational study, with 6-month data from Part A of the registrational study expected in mid-20...
NEW YORK and BASEL, Switzerland, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will present at the following investor conference...
News, Short Squeeze, Breakout and More Instantly...
Axovant Gene Therapies Ltd. Company Name:
AXGT Stock Symbol:
NYSE Market:
On-track to report t opline r esults from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to ra...
A pioneering researcher , Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapy Dr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of...
Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines Company’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 ...